Trials / Completed
CompletedNCT00789737
Welchol as Monotherapy for Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol as Monotherapy for Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 357 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The current study investigates Welchol as monotherapy to improve glycemic control in subjects with Type 2 Diabetes Mellitus not adequately controlled with diet and exercise alone. The study will evaluate if Welchol monotherapy for Type 2 Diabetes Mellitus will be safe, well tolerated and efficacious.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Welchol | Welchol 625mg tablets |
| DRUG | Placebo | placebo |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2008-11-13
- Last updated
- 2014-02-27
- Results posted
- 2014-01-22
Locations
107 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00789737. Inclusion in this directory is not an endorsement.